More recently, a pan-cancer analysis of 10,336 cancer cases performed with a custom next-generation sequencing gene panel (MSK-IMPACTTM, Memorial Sloan Kettering Cancer Center Integrated Mutation Profiling of Actionable Cancer Targets) provided relevant information regarding the distribution of TERT promoter variations in diverse tumour types and histological subtypes (Zehir et al., 2017). This evidence concerns the gene TERT and neoplasm.